- Home
- HBB vs ADCT Comparison
HBB vs ADCT Comparison
Compare HBB & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBB
- ADCT
- Stock Information
- Founded
- HBB 1904
- ADCT 2011
- Country
- HBB United States
- ADCT Switzerland
- Employees
- HBB N/A
- ADCT N/A
- Industry
- HBB Home Furnishings
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- HBB Consumer Discretionary
- ADCT Health Care
- Exchange
- HBB Nasdaq
- ADCT Nasdaq
- Market Cap
- HBB 242.8M
- ADCT 398.2M
- IPO Year
- HBB 2017
- ADCT 2020
- Fundamental
- Price
- HBB $14.71
- ADCT $3.26
- Analyst Decision
- HBB
- ADCT Strong Buy
- Analyst Count
- HBB 0
- ADCT 6
- Target Price
- HBB N/A
- ADCT $7.80
- AVG Volume (30 Days)
- HBB 23.7K
- ADCT 545.2K
- Earning Date
- HBB 10-29-2025
- ADCT 11-06-2025
- Dividend Yield
- HBB 3.20%
- ADCT N/A
- EPS Growth
- HBB N/A
- ADCT N/A
- EPS
- HBB 2.35
- ADCT N/A
- Revenue
- HBB $631,318,000.00
- ADCT $77,246,000.00
- Revenue This Year
- HBB N/A
- ADCT $13.10
- Revenue Next Year
- HBB N/A
- ADCT $6.23
- P/E Ratio
- HBB $6.22
- ADCT N/A
- Revenue Growth
- HBB N/A
- ADCT 15.73
- 52 Week Low
- HBB $12.72
- ADCT $1.05
- 52 Week High
- HBB $31.78
- ADCT $3.97
- Technical
- Relative Strength Index (RSI)
- HBB 49.22
- ADCT 52.13
- Support Level
- HBB $14.46
- ADCT $3.15
- Resistance Level
- HBB $15.01
- ADCT $3.38
- Average True Range (ATR)
- HBB 0.50
- ADCT 0.17
- MACD
- HBB 0.09
- ADCT -0.01
- Stochastic Oscillator
- HBB 45.41
- ADCT 39.45
About HBB Hamilton Beach Brands Holding Company
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products and Health.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).